(Reuters) – The European Medicines Agency said on Friday Eli Lilly’s weight-loss drug does not need a separate approval for the treatment of a sleep disorder called obstructive sleep apnea (OSA).
The health agency considered that the use of Mounjaro is already covered by the approved indication for weight management and that a separate indication for the treatment of moderate to severe OSA in adults with obesity is not needed.
(Reporting by Christy Santhosh in Bengaluru; Editing by Shailesh Kuber)
Comments